triazolam has been researched along with rifampin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Backman, JT; Kivistö, KT; Neuvonen, PJ; Olkkola, KT; Villikka, K | 1 |
| Chughtai, SA; Cohn, LA; Kaplan, M; Smith, AL; Unadkat, JD; Weber, A | 1 |
| Chimalakonda, A; Kim, S; Morgan, DG; Pizzano, JG; Pray, D; Sinz, MW; Zheng, M; Zoeckler, ME | 1 |
| Hasegawa, M; Inoue, R; Kakuni, M; Tahara, H; Tateno, C; Ushiki, J | 1 |
| Baneyx, G; Iliadis, A; Lavé, T; Meille, C; Parrott, N | 1 |
| Hasegawa, M; Tahara, H; Watanabe, M | 1 |
| Chang, JH; Li, R; Liu, L; Ly, JQ; Messick, K; Wong, S | 1 |
1 review(s) available for triazolam and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for triazolam and rifampin
| Article | Year |
|---|---|
Triazolam is ineffective in patients taking rifampin.
Topics: Adult; Antibiotics, Antitubercular; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Enzyme Induction; Female; Humans; Hypnotics and Sedatives; Male; Mixed Function Oxygenases; Rifampin; Triazolam | 1997 |
13 other study(ies) available for triazolam and rifampin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit.
Topics: Animals; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Hypnotics and Sedatives; Immunochemistry; In Vitro Techniques; Male; Microsomes, Liver; Organ Size; Oxidoreductases, N-Demethylating; Protein Binding; Rabbits; Rifabutin; Rifampin; Triazolam | 2001 |
Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: extrapolation to human CYP3A4 induction potential.
Topics: Animals; Antibiotics, Antitubercular; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Gene Expression Regulation, Enzymologic; Humans; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Models, Animal; Pregnane X Receptor; Receptors, Steroid; Rifampin; RNA, Messenger; Species Specificity; Triazolam | 2008 |
Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.
Topics: Animals; Biological Transport; Biotransformation; Chimera; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Inactivation, Metabolic; Liver; Male; Mephenytoin; Mice; Microsomes, Liver; Models, Animal; Pioglitazone; Pregnane X Receptor; Receptors, Steroid; Rifampin; RNA, Messenger; Thiazolidinediones; Triazolam; Warfarin | 2012 |
Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Topics: Alfentanil; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Hepatocytes; Humans; Midazolam; Models, Biological; Nifedipine; Rifampin; Tissue Distribution; Triazolam | 2014 |
A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
Topics: Alprazolam; Animals; Area Under Curve; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Drug Interactions; Hydrocortisone; Hydroxycholesterols; Macaca fascicularis; Male; Midazolam; Rifampin; Triazolam | 2019 |
Investigating the Utility of Humanized Pregnane X Receptor-Constitutive Androstane Receptor-CYP3A4/7 Mouse Model to Assess CYP3A-Mediated Induction.
Topics: Alkynes; Animals; Benzoxazines; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Drug Evaluation, Preclinical; Drug Interactions; Feasibility Studies; Female; Humans; Mice; Mice, Transgenic; Microsomes, Liver; Pioglitazone; Pregnane X Receptor; Rifampin; Species Specificity; Triazolam | 2021 |